Noom / Noom Med Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A medication program can be well described as a subscription and still be incompletely described as a treatment. That distinction matters with Noom / Noom Med. Its public documentation outlines digital behavior-change tools, access to independent clinical partners, medication-inclusive programs and a separate route for branded prescriptions. But a program name, receptor claim or introductory price does not establish exactly which preparation a patient will receive—or whether research on a particular medicine applies to that offering.

This review examines what Noom’s public documentation supports, rather than treating its marketing as a clinical performance report. Pages consulted October 19, 2026, describe a substantial service offering, but contain conflicting prices and uneven detail about geography, formulations and delivery. Some pages could not be reloaded during the final refresh; earlier documented copies inform this review. Current terms therefore need confirmation with Noom. The central question is not simply whether medication is available, but what can be verified before enrollment.

At a glance

Who provides medical care: Noom says it is not a healthcare provider; independent clinical partners make medical and pharmacy decisions.
Sources: [7]
Medication-inclusive advertised prices: The pricing page lists Microdose GLP-1Rx at $79 to start, then $179/month; GLP-1Rx at $129, then $249/month; and Plus at $149, then $299/month. Subsequent rates follow the first four-week supply and are billed quarterly.
Sources: [11]
Branded medication is separate: Telehealth for Branded Med is advertised at $39 to start and $129/month after month one, billed quarterly; medication is not included.
Sources: [11]
Product-review boundary: Noom says GLP-1Rx medications come from USP-compliant, state-regulated pharmacies but have not been reviewed by FDA for safety, efficacy or quality.
Sources: [5]
Availability is program-dependent: Current pricing documentation says programs are not available in all 50 states. An older article excludes Alabama and Virginia, but does not establish today’s program-by-program availability.
Sources: [11] [9]

Start with the product, not the program name

Noom’s menu includes Microdose GLP-1Rx, GLP-1Rx, GLP-1Rx Plus and Proactive Health GLP-1Rx. Plus is described as acting on both GLP-1 and GIP receptors, with clinical care, medication and the digital program included and no insurance required. Those descriptions identify commercial categories, not a complete medication specification. The consulted documentation does not establish the exact molecule, formulation and route for every named program, so readers should not fill those gaps using familiar branded products.

The branded route is more explicit about possible prescriptions: Noom names Ozempic, Wegovy and Zepbound, conditional on a clinician’s evaluation and treatment plan. A broader article also lists Rybelsus, Mounjaro, Saxenda, Victoza, Trulicity, Contrave, metformin, topiramate and Bydureon. This is a menu of potential prescribing options, not a promise that every drug is available through every subscription, in every state, or to every applicant.

The useful evidence request is therefore concrete: obtain the proposed medication’s name, formulation, route and dispensing pharmacy before assuming research applies. Our guide to formulation and route explains why those details matter. Noom’s oral metformin offering, for example, is distinct from its GLP-1 programs; its page explicitly states that metformin is not FDA-approved for weight loss.

What Noom’s pricing page says—and what each label leaves to confirm
Offering	Documented feature	Important clarification
Microdose GLP-1Rx	$79 to start; then $179/month after the first four-week supply, billed quarterly	Exact molecule, formulation and route are not established here
GLP-1Rx	$129 to start; then $249/month after the first four-week supply, billed quarterly	Do not assume a branded product from the program name
GLP-1Rx Plus	$149 to start; then $299/month after the first four-week supply, billed quarterly	GLP-1/GIP description is not a complete product specification
Proactive Health GLP-1Rx	$149 every four weeks; first term 15 weeks, renewals 16 weeks	Includes advertised home testing of 17 biomarkers
Telehealth for Branded Med	$39 to start; then $129/month after month one, billed quarterly	Medication costs are separate

Sources: [11] [5] [9] [3] [4]

Clinical research does not validate the whole subscription

Noom’s statement that GLP-1Rx medications are produced in USP-compliant, state-regulated pharmacies is a provider claim, not an independent pharmacy inspection or credential check. The same disclosure says those medications have not been reviewed by FDA for safety, efficacy or quality. The terms also refer to compounded prescriptions that must be dispensed through platform pharmacy partners. The consulted pages do not name the dispensing pharmacy for each program.

FDA explains that compounded preparations are not FDA approved and do not undergo its premarket review. That does not, by itself, prove clinical inequivalence, nor does it validate a particular preparation. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. This is a clinical appropriateness question, not something a subscription label resolves.

STEP 1 and SURMOUNT-1 studied specified subcutaneous semaglutide and tirzepatide regimens, respectively—not Noom’s service, unnamed preparations or microdose programs. Their results cannot establish outcomes for these offerings or predict an individual’s response. The distinction between approved medicines and compounded preparations is therefore central here. Noom’s documentation supports access claims more clearly than provider-specific effectiveness claims; it should not be read as a clinical trial of the platform.

Sources: [5] [7] [1] [3] [4]

Conflicting prices complicate the evidence trail

The pricing page provides usable numbers rather than merely inviting a consultation. Beyond its three principal GLP-1 tiers, it lists oral metformin at $69 to start and $99 per month after the first four-week supply, billed quarterly. Proactive Health is $149 every four weeks, with a 15-week first term and 16-week renewals. These periods are not interchangeable: four weeks is not a calendar month, and a stated subscription term does not independently establish medication quantity.

The homepage introduces different terms: an initial three-week subscription and four weeks of medication from $149 plus tax, followed by $349 per month plus tax for a 12-week subscription. Another homepage offer starts from $79 plus tax and continues at $199 per month plus tax for 12 weeks. Both disclosures specify new accounts and pricing effective March 31, 2026. The documentation does not establish that these offers are identical to the pricing-page tiers.

The Wegovy page adds two care-only schedules—$39 initially then $129 monthly, and $69 initially then $99 monthly—without explaining their respective applicability in that block. Both exclude medication. An April 2025 article also describes three-month upfront billing after the introductory month. Readers need an enrollment-specific written quote identifying the product, tax, collection schedule and renewal amount; selecting the lowest number across pages would misrepresent the available evidence.

Sources: [11] [5] [6] [9]

Enrollment connects separate organizations

Noom, Inc. operates the platform under its terms, but says it is not a healthcare provider and does not itself establish a patient-clinician relationship. Medical and pharmacy decisions belong to independent clinical partners. The pricing page describes a short online assessment, an eligibility review and connection with a clinician whom Noom describes as licensed. It also promises visibility into pricing, subscription costs and next steps before commitment.

Eligibility varies by program and may involve BMI, medical history and state of residence. The homepage excludes people under 18, people who are pregnant, those with an eating disorder and those who are underweight, defined there as BMI below 18.5. An April 2025 Noom Med article gives thresholds of BMI 30 or higher, or at least 27 with a weight-related condition. That older article should not be treated as the universal current rule for every newer program.

The Wegovy pathway specifically describes a metabolic laboratory test before online clinical evaluation, with prescribing only if clinically appropriate. Proactive Health separately advertises home testing of 17 biomarkers. Neither statement establishes a common testing protocol or included laboratory package across the entire menu. Before paying, readers can reasonably ask which clinical organization will evaluate them, which tests their particular plan requires and whether those tests carry separate charges.

Sources: [7] [11] [5] [9] [6]

Support is documented, but its roles differ

Noom Weight is the nonmedication behavior-change program, available separately and included with all medication plans according to the pricing page. Its tools include food and macro tracking, progress tracking, body scans, coaching and personalized lessons. The homepage also describes GLP-1 Companion with Muscle Defense, offering protein tracking, high-protein recipes and on-demand workouts. Those are documented program features; the branding does not establish a measured guarantee of muscle preservation.

For clinical support, the Noom Med article advertises unlimited one-to-one telehealth visits and chat messaging with specially trained weight-loss clinicians. It also describes a dedicated Care Team helping with insurance when applicable, fulfillment, prescription refills and potential side effects. These are useful contact paths, but the consulted documentation does not establish guaranteed human response times, required follow-up frequency or a uniform visit schedule for every current offering.

Coaching is not interchangeable with prescribing support. Noom’s terms say coaches cannot diagnose or treat medical or mental-health conditions, and coaching interactions do not create a physician-patient relationship. Questions about tolerability or medication instructions therefore belong with the clinical or pharmacy team. As our guide to clinical follow-up explains, continuing care concerns response and tolerance—not just whether a renewal payment succeeds.

Sources: [11] [9] [5] [7] [2]

Pharmacy and shipping claims have boundaries

Noom’s terms say most prescriptions may be filled at a pharmacy of the patient’s choice. There are important exceptions: certain compounded prescriptions can only be dispensed by a platform pharmacy partner, and some generic-medication programs require a preferred pharmacy to obtain that program and price. These restrictions matter when comparing access or trying to move an existing prescription. Dispensing arrangements also do not establish who compounded a preparation.

The homepage advertises medication shipped to the door in seven days, but the text does not define the starting point or establish a universal arrival guarantee. A separate disclosure says home delivery is unavailable for some medications and depends on insurance or cash-pay status. The branded program allows pickup or pharmacy delivery. Guaranteed evaluation, dispensing and arrival times—and cold-chain replacement procedures—are not established in the consulted documentation.

For injectable deliveries, FDA advises not using a GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. That advice is general regulatory guidance, not evidence of a Noom shipping problem. A practical pre-enrollment question is who handles a delayed or temperature-compromised shipment, how to reach them and what replacement arrangements apply. The seven-day marketing statement does not answer those questions.

Sources: [11] [5] [7] [1]

Insurance checking is not treatment approval

For branded medicines, Noom says it can help check potential insurance coverage. Medication is paid separately, through insurance if approved or through cash payment. Its pricing page says insurance does not cover the Noom program itself. The terms describe a different context for employer or private-plan access: clinical partners may submit claims, and clinical services may involve copays or deductibles. These statements concern different arrangements rather than one universal coverage rule.

The terms say Noom is not enrolled as a participating provider or vendor in federal or state healthcare programs, including Medicare and Medicaid. That limitation should not disappear behind the marketing statement that no insurance is required. Likewise, possible FSA/HSA reimbursement is conditional on the program, plan and provider; it is not a guaranteed reimbursement or a tax determination. An individual’s medication coverage still requires confirmation with the relevant insurer.

Noom’s insurance checker is informational: it does not initiate treatment requests or issue prescriptions. Its advertised first-month discount of $90 or more depends on program selection, and the starting $39 figure refers to the first-month subscription only, excluding medication. Completing that check therefore establishes neither clinical eligibility nor a complete treatment price. Readers should separate coverage information, subscription charges and the pharmacy’s medication charge when reviewing the result.

Sources: [11] [7] [8] [2]

Renewals and refunds require separate checks

Noom subscriptions renew automatically at the end of the disclosed billing period unless canceled. The terms require cancellation before 11:59 p.m. Eastern time on the day before the next recurring billing date to avoid another charge, and allow cancellation through the account. They ordinarily deny refunds or credits for partially used billing periods, while reserving discretion for exceptions. Stopping a renewal is therefore different from recovering an earlier payment.

The refund policy distinguishes clinical programs. For Noom Med, refunds may be available until a prescription is written; afterward the policy says they are no longer possible. For Telehealth for Branded Meds, possible refunds require a request within seven days of the first charge and before a clinical visit occurs. These are consequential service milestones, not simply deadlines tied to whether medication has arrived.

The broader documentation also contains qualifications: terms describe a three-business-day rescission provision for California residents, and cancellation during a trial or promotion may take effect immediately even though general cancellation guidance describes access through the cycle. Readers should confirm the applicable agreement rather than treating a support summary as an absolute rule. Our guide to what provider documents can prove offers a useful framework for separating a clear contractual statement from an unresolved enrollment detail.

Sources: [7] [10]

Questions & answers

Does Noom’s Microdose program have the same evidence as branded semaglutide?

The consulted documentation does not establish that. It does not fully identify Microdose’s molecule, formulation and route, and the cited clinical trials did not study Noom’s microdose program. Ask for the actual prescription details and the evidence offered for that preparation. Research on a specified branded-drug regimen cannot automatically validate a differently described service.

Sources: [11] [3] [4]

Is medication included in every Noom Med price?

No. The branded-medication telehealth subscription explicitly excludes medication, although it includes clinical care, prescribing services and the digital program. Several other offerings advertise medication-inclusive pricing. Because homepage and pricing-page figures differ, obtain a written quote showing the exact program, medication, introductory period, recurring billing interval, tax and any separate pharmacy or delivery charges.

Sources: [11] [5]

Can I use Noom Med in Alabama or Virginia?

An April 2025 article excludes Alabama and Virginia, while the pricing page says programs are not available in all 50 states without providing a complete current list. Those statements do not establish present availability for each product. Use the program-specific eligibility check and confirm your state before assuming either access or exclusion across Noom’s entire menu.

Sources: [11] [9]

Can I choose my own pharmacy?

Often, but not universally. Noom’s terms permit patient-selected pharmacies for most prescriptions. Certain compounded prescriptions must use platform pharmacy partners, and some generic programs require a preferred pharmacy to access that program’s pricing. Ask which restriction applies to the proposed prescription and request the pharmacy’s identity; the consulted documentation does not identify each program’s dispensing partner.

Sources: [7]

Does Noom provide clinical care in Spanish?

The consulted documentation does not confirm Spanish-language clinical visits or translated consent materials. The terms state that the agreement and related documents are in English, but that does not establish every language available for care. If language access matters, confirm the language of the consultation, pharmacy instructions, messaging and consent process before paying or completing a clinical encounter.

Sources: [7]

Can I get a refund if no medication has shipped?

Shipment is not the stated controlling milestone. The Noom Med policy cuts off refunds once a prescription is written; the branded-telehealth policy requires a request within seven days of the first charge and before a clinical visit. Other contractual provisions may apply, including the California rescission provision. Canceling renewal alone does not establish refund eligibility.

Sources: [10] [7]

Our assessment

Noom documents more than a prescription checkout: its offering includes behavior-change tools, access to independent clinicians, advertised ongoing telehealth support, several medication pathways and help navigating branded-drug coverage. Those are meaningful service features. The documentary weaknesses are equally material: inconsistent prices, incomplete product specifications, unnamed program-specific pharmacies and no complete current state matrix. Its pharmacy-quality statements and digital-program branding should not be mistaken for independent verification or provider-specific clinical outcomes. Before enrollment, the most useful next step is a written, program-specific explanation of the medication, pharmacy, total charges, clinical follow-up and refund milestones. Noom is clearly a medication-access platform in the consulted documentation; how well a particular offer matches published drug evidence remains a separate question that the program name alone cannot answer.

Visit Noom / Noom Med’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Noom / Noom Med Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the program name

02Clinical research does not validate the whole subscription

03Conflicting prices complicate the evidence trail

04Enrollment connects separate organizations

05Support is documented, but its roles differ

06Pharmacy and shipping claims have boundaries

07Insurance checking is not treatment approval

08Renewals and refunds require separate checks